Nurix Therapeutics (NRIX) EBT Margin Growth (1y) (2020 - 2026)
Powered by 
Analysis
Nurix Therapeutics (NRIX) EBT Margin Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -153.00 |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | -571.00 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 553.00 |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 4,709.00 |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 1,076.00 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 1,911.00 |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -392.00 |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 29,565.00 |
| 10 | Nurix Therapeutics | 2.86 Bn | 2.42 Bn | - | -89,617.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -89,617.00 |
| Feb 28, 2026 | -108,896.00 |
| Nov 30, 2025 | -13,544.00 |
| Aug 31, 2025 | -70,651.00 |
| May 31, 2025 | 27,072.00 |
| Feb 28, 2025 | -5,558.00 |
| Nov 30, 2024 | -16,392.00 |
| Aug 31, 2024 | -18,800.00 |
| May 31, 2024 | -28,851.00 |
| Feb 29, 2024 | 7,132.00 |
| Nov 30, 2023 | 41,196.00 |
| Aug 31, 2023 | 22,332.00 |
| May 31, 2023 | 31,800.00 |
| Feb 28, 2023 | 12,097.00 |
| Nov 30, 2022 | -17,957.00 |
| Aug 31, 2022 | -14,112.00 |
| May 31, 2022 | -2,705.00 |
| Feb 28, 2022 | 4,093.00 |
| Nov 30, 2021 | -21,207.00 |
| Aug 31, 2021 | 17,083.00 |